Scientific publication with Newspaper speed
HIGH IMPACT, OUTSTANDING EDITORIAL BOARD, OVERNIGHT PUBLICATION, OPEN ACCESS, PROMOTION, HIGH VISIBILITY
Oncotarget publishes high-impact research papers of general interest and outstanding significance and novelty in all areas of biology and medicine: in translational, basic and clinical research including but not limited to oncogenes, oncoproteins and tumor suppressors, signaling pathways as potential targets for therapeutic intervention, shared targets in different diseases (cancer, benign tumors, atherosclerosis, eukaryotic infections, metabolic syndrome and other age-related diseases), chemotherapy and new therapeutic strategies.
To ensure the highest impact on the field, we now publish Priority articles and reviews over-(two)-night in PubMed.
If your paper was mistakenly rejected by other leading journals, you may submit it to Oncotarget (see our unique 2 night policy) together with peer-reviews obtained from the other journal and rebuttal letter.
Under supervision of Oncotarget's editors and editorial board, Oncotarget now launches Oncoscience, a sister peer-reviewed journal, on all topics in cancer research. The main criteria for publication in Oncoscience is high-quality design and execution of the study, high-quality results and clear conclusions supported by the data.
|12/30/2013||Our new submission system is online oncotarget.msubmit.net. See link for earlier papers.|
|06/21/2013||New IF: IF2012 = 6.636|
|06/19/2012||Launched in 2010 Oncotarget has received its first IF 2011 = 4.784|
|01/18/2012||A digital archive of papers published in Oncotarget is now available though the U.S. National Library of Medicine's PubMed Central (PMC) database.|
|12/21/2010||Oncotarget has been accepted for indexing at PubMed/Medline. All papers have appeared on PubMed/Medline.|
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
Copyright @ 2008-2013 Impact Journals LLC. All rights reserved.